DDR2 and carcinoma: Inhibiting DDR1 or DDR2 with nilotinib (Jeitany et al, 2018), dasatinib (Hammerman et al, 2011; von Massenhausen et al, 2016), or other non‐approved inhibitors (Ambrogio et al, 2016; Grither & Longmore, 2018) was shown to decrease tumorigenicity, invasion, or metastasis of several carcinomas (Corsa et al, 2016).